AnalystsJeffrey HolfordJeffrey Holford's Stock Forecasts
AnalystsJeffrey Holford
Analyst Ranking
Top 45%
#2206 out of 4929 analysts
Average Return
+7.87%
Win Rate
80%4 out of 5
Risk vs Reward
Poor
Good
Jeffrey Holford's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Eli Lilly & CoLLY | +28.30% | $82.44 | $105.77 | 2017-09-15 - 2018-09-14 | Strong Buy |
Abbvie IncABBV | +9.51% | $87.37 | $95.68 | 2017-09-15 - 2018-09-14 | Strong Buy |
Bristol Myers Squibb CoBMY | +1.87% | $62.48 | $63.65 | 2017-09-15 - 2017-10-16 | Strong Buy |
Parker Hannifin CorpPH | +1.71% | $707.05 | $719.15 | 2025-01-31 - 2025-07-03 | Strong Buy |
Jeffrey Holford Analyst Color
Get additional color on Jeffrey Holford's coverage of popular stocks
Jeffrey Holford's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Parker Hannifin CorpPH | 1 | Strong Buy | $790.00 | +9.85% | Maintains | 5 months ago |
Astrazeneca PLCAZN | 1 | Hold | $42.00 | N/A | Assumes | 7 years ago |
Merck & Co IncMRK | 1 | Hold | N/A | N/A | Upgrades | 8 years ago |
Bristol Myers Squibb CoBMY | 2 | Hold | N/A | N/A | Downgrades | 8 years ago |
Johnson & JohnsonJNJ | 1 | Strong Buy | N/A | N/A | Upgrades | 8 years ago |
Eli Lilly & CoLLY | 1 | Strong Buy | $96.00 | N/A | Maintains | 8 years ago |
Abbvie IncABBV | 1 | Strong Buy | $107.00 | N/A | Maintains | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.